Table 2.
Characteristics of PLHIV stratified by adverse reactions after COVID-19 vaccination (N = 527)
| Variables | |
Adverse reactions |
Univariable |
Multivariable |
||
|---|---|---|---|---|---|---|
| Overall | Yes | No | P-value | aOR (95% CI) | P-value | |
| Total | 527(100.0%) | 155(29.4%) | 372(70.6%) | |||
| Gender | 0.177 | |||||
| Male | 503(95.4%) | 145(93.5%) | 358(96.2%) | Ref | ||
| Female | 24(4.6%) | 10(6.5%) | 14(3.8%) | 1.81(0.76–4.17) | 0.168 | |
| Age | 0.353 | |||||
| 18–29 | 186(35.3%) | 46(29.7%) | 140(37.6%) | Ref | ||
| 30–39 | 240(45.5%) | 78(50.3%) | 162(43.5%) | 1.49(0.97–2.30) | 0.071 | |
| 40–49 | 76(14.4%) | 24(15.5%) | 52(14.0%) | 1.37(0.75–2.46) | 0.299 | |
| ≥50 | 25(4.7%) | 7(4.5%) | 18(4.8%) | 1.19(0.44–2.93) | 0.715 | |
| BMI | 0.245 | |||||
| <18.5 | 39(7.4%) | 7(4.5%) | 32(8.6%) | - | ||
| 18.5–24 | 327(62.0%) | 101(65.2%) | 226(60.8%) | - | ||
| ≥24 | 161(30.6%) | 47(30.3%) | 114(30.6%) | - | ||
| Received influenza or pneumonia vaccine inthe past 3 years | 0.511 | |||||
| Yes | 426(80.8%) | 128(82.6%) | 298(80.1%) | - | ||
| No | 101(19.2%) | 27(17.4%) | 74(19.9%) | - | ||
| Time of HIV diagnosis | 0.120 | |||||
| ≤5 year | 336(63.8%) | 91(58.7%) | 245(65.9%) | - | ||
| >5 year | 191(36.2%) | 64(41.3%) | 127(34.1%) | - | ||
| On ART | 0.216 | |||||
| Yes | 508(96.4%) | 147(94.8%) | 361(97.0%) | - | ||
| No | 19(3.6%) | 8(5.2%) | 11(3.0%) | - | ||
| ART duration | 0.184 | |||||
| ≤5 years | 350(68.9%) | 95(64.6%) | 255(70.6%) | - | ||
| >5 years | 158(31.1%) | 52(35.4%) | 106(29.4%) | - | ||
| Latest HIV viral load (copies/ml) | 0.661 | |||||
| <50 | 387(73.4%) | 118(76.1%) | 269(72.3%) | - | ||
| ≥50 | 54(10.2%) | 14(9.0%) | 40(10.8%) | - | ||
| Not sure | 86(16.3%) | 23(14.8%) | 63(16.9%) | |||
| Latest CD4+ T cell count (cells/μl) | 0.309 | |||||
| <200 | 15(2.8%) | 3(1.9%) | 12(3.2%) | |||
| 200–500 | 172(32.6%) | 43(27.7%) | 129(34.7%) | - | ||
| >500 | 291(55.2%) | 92(59.4%) | 199(53.5%) | - | ||
| Not sure | 49(9.3%) | 17(11.0%) | 32(8.6%) | - | ||
| Comorbidities | 0.392 | |||||
| Yes | 68(12.9%) | 23(14.8%) | 45(12.1%) | - | ||
| No | 459(87.1%) | 132(85.2%) | 327(87.9%) | - | ||
PLHIV, people living with HIV; aOR, adjusted odds ratio; CI, confidence interval; BMI, body-mass index.
ART, antiretroviral therapy.
Comorbidities include hyperlipidemia, liver disease, kidney disease, hypertension, allergic rhinitis, allergic dermatitis, respiratory diseases, diabetes, cardiovascular diseases.